Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20

Marta Pillon, E. Carraro, L. Mussolin, V. Conter, A. Tondo, M. Aricò, R. Mura, A. Sala, L. Vinti, S. Buffardi, P. Pierani, E. S.G. d'Amore, G. Basso

Research output: Contribution to journalArticlepeer-review

Abstract

Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.

Original languageEnglish
Article numbere26855
JournalPediatric Blood and Cancer
Volume65
Issue number2
DOIs
Publication statusPublished - Oct 19 2017

Keywords

  • AIEOP LNH-97
  • childhood
  • NHL
  • PMLBL

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20'. Together they form a unique fingerprint.

Cite this